Please be advised that due to the high volume of submissions, the ANZCTR is currently experiencing delays in processing submissions. Please allow additional time for registration or updates to registration records. As the ANZCTR is funded by Australia and New Zealand, we must prioritise submissions from these countries first, therefore international submissions will experience further delays. Apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
A double-blind, randomised study on the effects of STW 5 on symptoms and immunologic function in patients with irritable bowel syndrome
Scientific title
A double-blind, randomised study on the effects of STW 5 on symptoms and immunologic function in patients with irritable bowel syndrome
Secondary ID [1] 281172 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Irritable Bowel Syndrome 3786 0
Condition category
Condition code
Oral and Gastrointestinal 3962 3962 0 0
Inflammatory bowel disease

Study type
Description of intervention(s) / exposure
This is a cross over study examining the effects of a herbal preperation, Iberogast (STW 5) and placebo for patients suffering from Irritable Bowel Syndrome compared to healthy controls. Iberogast is a liquid consisting of 9 plant extracts. Each treatment arm is conducted over 2 weeks. Study medication is administered at 20 drops 3 times per day, orally. With a washout period of 1 week between treatment arms.
Intervention code [1] 3502 0
Treatment: Other
Intervention code [2] 3947 0
Early detection / Screening
Comparator / control treatment
cross over design: healthy volunteers and Iriitable Bowel Syndrome (IBS) subjects will receive 2 weeks of herbal preparation and 2 weeks of placebo. The placebo has been prepared to taste similar to Iberogast. Placebo liquid is taken orally, 20 drops 3 times a day for the duration of 2 weeks. The Placebo consists of ethanol 28-34% (v/v),herbal flavour and liquorice flavour. A Washout period of one week between treatments.
Control group

Primary outcome [1] 4866 0
To assess the improvement of symptoms in patients with IBS during treatment with the herbal preparation, Iberogast (STW 5) and placebo the subject will complete previously standardised questionnaires
Timepoint [1] 4866 0
Visit 1 baseline, visit 2 week 2, visit 3 week 4, visit 4 week 5, visit 5 week 7.
Secondary outcome [1] 8210 0
Through analysis subjects blood sample at visit 1,3,4 and 5 we will measure the influence of the treatment on Peripheral Blood Monouclear cell (PBMC)-mediated cytokine secretion and gut homing T cells.
Timepoint [1] 8210 0
Visit 1 baseline, visit 3 week 4, visit 4 week 5, visit 5 week 7

Key inclusion criteria
Symptoms consitent with IBS according to the Rome III criteria; Not recieved antibiotics 8 wks prior; Not taking immunosuppressive medications;No Laxatives, no prokinetic drugs for 2 weeks;
Able to sign consent
Minimum age
18 Years
Maximum age
80 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Previous abdominal or gynaecological surgery (except appendectomies and cholecystectomies) previous gastrointestinal cancer;Known peptic ulcers;pregnancy or breastfeeding;chronic inflammatory disease, cardiovascular disease; respiratory disease;Diabetes mellitus; Epilepsy;

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 3970 0
Commercial sector/Industry
Name [1] 3970 0
STEIGERWALD Arzneimittelwerk GmbH
Address [1] 3970 0
Havelstr. 5, D-64295 Darmstadt

Adelaide SA 5000
Country [1] 3970 0
Funding source category [2] 4458 0
Name [2] 4458 0
Royal Adelaide Hospital Gastroenterology & Hepatology Unit
Address [2] 4458 0
Ward Q7
North Terrace
Adelaide SA 5000
Country [2] 4458 0
Primary sponsor type
Royal Adelaide Hospital Gastroenterology and Hepatology
Ward Q7
North Terrace
Adelaide SA 5000
Secondary sponsor category [1] 4017 0
Government body
Name [1] 4017 0
Department of Health (DoH)
Address [1] 4017 0
Level 13, 11 Waymouth Str, Adelaide SA 5000
Country [1] 4017 0

Ethics approval
Ethics application status

Brief summary
The study is designed to provide information about the way the gastroinstestinal tract responds to the treatment of herbal medication Iberogast.We seek to determine the effects of Iberogast on symptoms and stool frequencey as well as immunologic function.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 29000 0
Address 29000 0
Country 29000 0
Phone 29000 0
Fax 29000 0
Email 29000 0
Contact person for public queries
Name 12157 0
Dr Jane Andrews
Address 12157 0
Gastroenterolgy Unit Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Country 12157 0
Phone 12157 0
088222 5207
Fax 12157 0
Email 12157 0
Contact person for scientific queries
Name 3085 0
Dr Jane Andrews
Address 3085 0
Gastroenterolgy Unit Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Country 3085 0
Phone 3085 0
088222 5207
Fax 3085 0
Email 3085 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary